BioCentury
ARTICLE | Financial News

Protagonist files for IPO

July 13, 2016 12:47 AM UTC

Protagonist Therapeutics Inc. (Milpitas, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Leerink, Barclays and BMO Capital Markets.

Protagonist develops oral peptides to treat gastrointestinal diseases. By year end, Protagonist expects to begin a Phase IIb study of PTG-100, an integrin alpha(4)beta(7) peptide antagonist, to treat ulcerative colitis (UC). Next year, it plans to start a Phase I study of PTG-200, an oral peptide interleukin-23 (IL-23) receptor antagonist, to treat UC. ...